Tag:
Sutent
Latest Headlines
Latest Headlines
Bayer's Nexavar falters in another lung cancer trial
Nexavar did deliver "an improvement" in progression-free survival, the companies said, but that was the study's secondary endpoint.
Gene study finds tumor-cell flaw possibly vulnerable to Pfizer, AZ cancer meds
More evidence that drugs and diagnostics will be playing together often: Researchers sequencing genes in colon and lung tumors found mutations that could be targeted with existing drugs. The study
DNA sequencing exposes new uses for Pfizer targeted cancer drugs
As pharma companies expand their use of DNA sequencing for drug R&D, researchers have uncovered some potential new targets for existing cancer drugs that are likely to spur further use of
AB soars on promising survival data from Phase II tumor study
Shares of Paris-based AB Science shot up yesterday after the drug developer reported strong efficacy results from a midstage study of its experimental drug for gastrointestinal tumors. The treatment,
Pfizer, Novartis drugs win advisory panel nod
FDA's expert advisors gave two thumbs up yesterday, one for Pfizer ( $PFE ) and one for Novartis ( $NVS ). The companies' cancer drugs Sutent and Afinitor won backing from the panel as treatments for a
Novartis, Pfizer see cancer data questioned
With cancer drugs, the first approval is only the beginning. An indication for one type of cancer can become two or three if drugmakers play their cards right--and if the treatments themselves prove
Steve Jobs might benefit from new cancer drugs
When Steve Jobs began another medical leave last week, Apple didn't release any details about its CEO's health. But that hasn't stopped observers from conjecturing. Bloomberg takes a close look at
GSK pitches Votrient rebate if trial favors Sutent
Drugmakers have held out plenty of different carrots to induce the U.K.'s cost-effectiveness watchdog to accept expensive meds for use on the National Health Service. Companies have offered paybacks
In new setback, Pfizer halts Sutent trial
In its second strike-out in two months, Pfizer's cancer drug Sutent has whiffed a trial in prostate cancer. The company stopped the trial, which was studying Sutent plus prednisone as a treatment for
Pfizer's Sutent falls flat in lung cancer
More bad news in Pfizer's ( NYSE: PFE ) campaign to broaden use of its kidney-cancer superstar Sutent . In a new study in lung cancer, Sutent failed to prolong patients' lives, though it did stall
